

CASE STUDY SUBMISSION

Important: In observance of HIPAA and the sacred trust between care giver and patient, absolutely no patient names or identifying information is to be disclosed. Patient privacy is to be preserved. If you attach any medical records, pathology, surgical or laboratory reports, all names are to be removed.

Date				
Clinician Name & Credentials				
Email				
Describe Your Patient (Please	e SUMMARIZE and use eco	nomy of words. You w	rill have 15 minutes to	present)
Age, Gender & Ethnicity				
Body Type				
Values				
What is most important to this patient? (Quality of Life, Decision Making, Side Effects?)				
Stress Resilience				
Other				
Primary Diagnosis & Date				
(ex. Breast Cancer L, T3 N1 M0, BRCA1 positive, grade 3, Ki67 > 45%)				
Secondary Diagnosis				
(ex. Diabetes Type 2, Obesity)				
Patient Status				
☐ New Diagnosis ☐ Recurre	ence 🗆 In Treatment	☐ In Recovery	☐ In Remission	☐ At Risk
Concomitant and/or Complicating Factors (ex: poorly controlled diabetes,				
insomnia, poor support system)				
Adverse Effects of Cancer or Cancer Treatments (ex. anxiety-depression, diarrhea, peripheral neuropathy)				
Relevant Laboratory, Pathology & Medical Reports				
(attach a PDF with patient identifying information removed or summarize)				



Brief Summary of Recent History				
Brief Summary of Additional Relevant Health, Medical, Psycho-Social and/or Family History				
Other Relevant Information Such as Chinaga as Avanged diagnosis Naturepathic/Lomponethic Information etc. (av. Liver Oi Stagnotion Dychicaia)				
Such as Chinese or Ayurvedic diagnosis, Naturopathic/Homeopathic Information, etc. (ex. Liver Qi Stagnation, Dysbiosis)				
Prior Community of Palaceted Part Consulations on Marking Liver Liver to a state of the Consulation of the C				
Brief Summary of Relevant Past Oncology or Medical Treatments (ex. surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, drug therapy)				
Summary of Recent and Current Treatments				
Medical Oncology Care (surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, drug therapy)				
Integrative Oncology Care (nutraceutical, botanical, phytochemical, acupuncture, energy medicine, other)				
Your 2 Core Questions (stated clearly and succinctly)				
1.				
2.				
Attached Medical Records for Reference (with patient identifying information removed)				



Integrative Oncology Professional Training Program

Case Study from S Shahab Multiple Myeloma 09.30.17

Studies show that early intervention is preferable to waiting and watching a smoldering MM Revlimid + Dexamethasone and/or Velcade(no green tea with Velcade)

Manage Inflammation Bone Health Hypercoagulation NFkB and AKT pathways

Active agens

Sulphoraphanes Broccoprotect 2/2x/day Low Dose DHEA 5-25 mg q am Licorice Root extract 2 teaspoons daily (Gan Cao) Ursolic Acid (Oldenlandia/Heydotis, Sage, Rosemary)

ursolic acid, found in basil, apples, prunes, and cranberries, for its ability to suppress STAT3 activation.

Pure Honokiol (magnolia bark) 3 caps x day Vitamin D 75 Berberine 500mg tid Ganoderma Isatis Ban Lan Gen Curcumin

Hypercoagulation
Omega 3 FA
Curcumin
Salvia Milthiorrhiza Dan Shen 2 teaspoons dailiy
Proteolytic enzymes (Wobenzyme or similar)

Clinical Synergy Modified Citrus Pectin 1 5g scoop 3x.day

Protect bones Osteoben 2/2x/day Restore Right+Psoralea+Epimedium+White Peony

Adaptogen

Natura Health Products POWER ADAPT 1 teaspoon twice daily

Custom Tonic (TBD) 1 teaspoon 2x/day Magnolia



www.AIIORE.com

Integrative Oncology Professional Training Program

Rabdosia

Licorice Root

Green Tea (if not on Velcade)

Astragalus

Ganoderma

Chaga

Cordyceps

Scutellaria baicalensis

Ashwaganda

Milk Thistle

Ginger

Schisandra

Lycium

Tang Kuei

Gotu Kola

Licorice Root

Dan Shen Salvia milt.

SCHEMA OF PATHOPHYSIOLOGY

* usually in the:bone marrow (myeloma) but can

Plasma cells also be extra-medullary

* solitary or multiple osteolytic lesions

Skeletal Finding: * diffuse osteoporosis associated effects * elevated serum calcium

of bone * hypercalciuria destruction * loss of height

extra skeletal * most commonly in head/neck area, e.g. myeloma nasopharynx., Also found in liver, kidneys

(i.e., outside bone) and other soft tissues

* anemia, abnormal clotting

peripheral * leukopenia, thrombocytopenia

blood * plasma cell leukemia

* circulating monoclonal B lymphocytes

* hyperproteinemia 80-150 gr/1



Integrative Oncology Professional Training Program

<u>www.AIIORE.com</u>

* hypervolemia

* monoclonal immunoglobulins (IgG, IgD, IgA,

plasma IgM, IgD, light chains)

protein changes

* amyloidosis

* narrowed anion gap

- * elevated serum B-2-microblogulin
- * decreased serum albumin
- * elevated serum Il-6 and C.R.P. (C reactive protein)

* proteinuria, casts, without leucocytes or

kidney erythrocytes

abnormalities * tubular dysfunction with acidosis and uremia

Of myeloma patients, 93% have multiple bone lesions and 3% have only one lesion. The remaining 4% who have only extra-skeletal lesions represent a sub-group with distinct disease and treatment characteristics; this sub-group will not be dealt within the context of this booklet.

Types of Monoclonal Proteins (M-components) Percentages/Totals

Serum types:

IgG 52

21

IgA

75%

IgD 2

H chains (G or A) only

IgE <0.01

Urine (Bence Jones only) types K (Kappa) L (lambda) 11%

<1

2 or more monoclonal paraproteins

<1



Integrative Oncology Professional Training Program

2%

no monoclonal paraprotein		1		
*IgM	12%			

*IgM (rarely myeloma) typically associated with Waldenstroms macroglobulinemia rather than myeloma.

Source: Data on 1,827 myeloma patients, collected and analyzed by Pruzanski and Ogryzlo, 1970.

The plasma volume rises due to the elevated total serum protein content. It can cause pseudo hyponatraemia (low serum sodium) and narrowed anion gap. High concentrations of myeloma protein can give a clinical "hyperviscosity syndrome."